Literature DB >> 25841444

EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy.

Jair Bar1, Damien Urban2, Roni Borshtein3, Hovav Nechushtan4, Amir Onn3.   

Abstract

Entities:  

Year:  2013        PMID： 25841444     DOI： 10.3978/j.issn.2304-3865.2012.12.03

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


× No keyword cloud information.
  6 in total

1.  Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.

Authors:  Cheng-Zhi Zhou; Yin-Yin Qin; Zhan-Hong Xie; Jie-Xia Zhang; Ming Ou-Yang; Shi-Yue Li; Rong-Chang Chen
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

2.  Safety and feasibility of video-assisted thoracoscopic surgery for stage IIIA lung cancer.

Authors:  Wenlong Shao; Jun Liu; Wehua Liang; Hanzhang Chen; Shuben Li; Weiqiang Yin; Xin Zhang; Jianxing He
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

3.  Long-term survival outcomes of video-assisted thoracic surgery for patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Xinguo Xiong; Hanzhang Chen; Jun Liu; Weiqiang Yin; Shuben Li; Xin Xu; Xin Zhang; Jianxing He
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

4.  Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.

Authors:  Guiping Yu; Ning Zhong; Guoqiang Chen; Bin Huang; Song Wu
Journal:  Tumour Biol       Date:  2014-07-21

5.  Size of solitary pulmonary nodule was the risk factor of malignancy.

Authors:  Chang-Zheng Shi; Qian Zhao; Liang-Ping Luo; Jian-Xing He
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

Review 6.  Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives.

Authors:  Xinghua Cheng; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2014-09-23       Impact factor: 4.147
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.